Skip to main content

SwitchCheckMedicines Reclassification

Changing the legal classification of medicines is a key driver of innovation for pharmaceutical and consumer healthcare companies. By reclassifying medicines from prescription-only (POM) to over-the-counter (OTC), “switching” can broaden access to powerful treatments, offer competitive advantages to your portfolio, and even establish new OTC therapy areas.

What is SwitchCheck?

View

Why trust SwitchCheck for your reclassification project?

View

What is SwitchCheck?

SwitchCheck offers expert advice and support throughout the switch process – from candidate selection and evaluation through to agency engagement, application and launch. We can help you choose the right switch candidates, assess feasibility, identify and manage potential challenges, and act as an expert partner throughout the application process.

Whether you need targeted support for specific stages of your switch project or a trusted partner to act as the overall medical lead, SwitchCheck offers a tailored service to meet your requirements.

Why trust SwitchCheck for your reclassification project?

Our team has extensive experience in medicines reclassification, working across diverse categories, including:

  • analgesia 
  • erectile dysfunction 
  • sleep 
  • migraine 
  • women’s health.

Our Managing Director, James Walmsley, is a recognised leader in POM-P switches. In 2023, he chaired the AESGP advisory board on switching, addressing both challenges and future opportunities. James frequently shares his expertise with pharmaceutical professionals, presenting on the complexities and benefits of switching.

Here’s how SwitchCheck can support your team:

  • Advice on candidate selection

  • Support for agency meetings

  • Claims development

  • Identification of data requirements

  • Benefit-risk assessment

  •  Launch support

  • Clinical overviews

  • Assessment against criteria for prescription-only status

Interested in our services? Please get in touch.

Contact